ACADIA PHARMACEUTICA

ACAD

Delayed - 03/08 04:00:00 pm
45.78USD	-6.53%

05/06/21	Q1 2021 Earnings Release (Projected)
08/11/21	Interim 2021 Earnings Release (Projected)
11/09/21	Q3 2021 Earnings Release (Projected)
03/01/22	FY 2021 Earnings Release (Projected)

03/01/21 \| 12:20pm	Cowen & Co. Health Care Conference
02/26/21 \| 10:40am	SVB Leerink Global Healthcare Conference
02/24/21 \| 04:30pm	FY 2020 Earnings Call
02/24/21 \| 04:05pm	FY 2020 Earnings Release

03/09/21 \| 10:20am	CRISPR THERAPEUTICS AG : Barclays Global Healthcare Conference
03/09/21	QIAGEN N.V. : Barclays Global Healthcare Conference
03/09/21 \| 07:00am	DENALI THERAPEUTICS INC. : H.C. Wainwright Global Life Sciences Conference
03/09/21 \| 07:00am	TG THERAPEUTICS, INC. : H.C. Wainwright Global Life Sciences Conference

03/07/21	BIO-TECHNE CORPORATION : Association of Biomolecular Resource Facilities Exhibition
03/06/21	GILEAD SCIENCES, INC. : Retroviruses and Opportunistic Infections Conference
03/04/21 \| 12:10pm	GILEAD SCIENCES, INC. : Cowen & Co. Health Care Conference
03/04/21 \| 01:00am	ARGENX SE : FY 2020 Earnings Release

Previous year

Next Year

Annual results		2016	2017	2018	2019	2020	2021 (e)
Sales M $	Released Forecast Spread	17,3 14,4 20%	125 126 -0,98%	224 224 0,03%	339 338 0,45%	442 444 -0,45%	638
Operating income (EBITDA) M $	Released Forecast Spread	-271 -265 -2,1%	-290 -298 2,8%	-244 -250 2,2%	-244 -248 1,7%	-284 -294 3,4%	-269
Operating profit (EBIT) M $	Released Forecast Spread	-273 -271 -0,59%	-292 -294 0,69%	-247 -251 1,3%	-247 -248 0,48%	-287 -296 3,1%	-280
Pre-Tax Profit (EBT) M $	Released Forecast Spread	-270 -272 0,67%	-288 -289 0,24%	-244 -247 1,4%	-234 -238 1,6%	-281 -289 2,9%	-276
Net income M $	Released Forecast Spread	-271 -270 -0,35%	-289 -293 1,2%	-245 -249 1,7%	-235 -238 1,3%	-282 -290 2,8%	-274
EPS $	Released Forecast Spread	-2,34 -2,35 0,26%	-2,36 -2,40 1,7%	-1,94 -1,99 2,5%	-1,60 -1,62 1,4%	-1,79 -1,84 2,8%	-1,70
Announcement Date		02/28/2017	02/27/2018	02/26/2019	02/26/2020	02/24/2021

Previous period

Next period

Quarterly results		2018 Q3	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1 (e)	2021 Q2 (e)	2021 Q3 (e)	2021 Q4 (e)	2022 Q1 (e)
Sales M $	Released Forecast Spread	58,3 56,3 3,5%	59,6 59,5 0,18%	63,0 60,9 3,3%	83,2 72,5 15%	94,6 88,5 6,9%	98,3 96,7 1,7%	90,1 90,8 -0,77%	110 103 6,5%	121 119 1,5%	121 123 -1,4%	113	143	173	211	193
Operating income (EBITDA) M $	Released Forecast Spread	-60,5 -76,0 20%	-66,5 -68,3 2,6%	-87,2 -76,1 -15%	-56,8 -70,8 20%	-45,1 -61,9 27%	-55,8 -61,8 9,7%	-88,9 -95,4 6,9%	-43,7 -67,7 36%	-84,9 -59,5 -43%	-66,3 -80,2 17%	-94,6	-77,8	-29,2	-21,8
Operating profit (EBIT) M $	Released Forecast Spread	-61,3 -71,6 14%	-67,3 -70,2 4,2%	-87,6 -77,1 -14%	-57,1 -68,3 16%	-45,4 -60,3 25%	-56,4 -57,9 2,6%	-89,5 -75,5 -19%	-44,0 -71,6 38%	-85,9 -58,0 -48%	-67,2 -76,5 12%	-93,5	-80,8	-59,4	-40,0	-12,1
Pre-Tax Profit (EBT) M $	Released Forecast Spread	-61,8 -70,1 12%	-65,5 -69,4 5,6%	-84,9 -76,2 -12%	-54,6 -67,3 19%	-42,2 -58,4 28%	-52,6 -56,4 6,7%	-88,0 -74,5 -18%	-41,7 -69,4 40%	-84,9 -58,0 -46%	-66,3 -74,6 11%	-92,8	-79,6	-57,9	-39,6	-12,1
Net income M $	Released Forecast Spread	-62,1 -70,6 12%	-65,5 -69,7 6,0%	-85,3 -75,9 -12%	-54,9 -68,3 20%	-42,0 -59,0 29%	-53,0 -56,4 6,0%	-88,0 -74,2 -19%	-42,1 -69,2 39%	-84,7 -57,7 -47%	-66,8 -74,9 11%	-92,4	-79,8	-66,1	-39,0	-12,1
EPS $	Released Forecast Spread	-0,50 -0,57 13%	-0,50 -0,55 8,8%	-0,59 -0,53 -11%	-0,38 -0,46 18%	-0,29 -0,40 28%	-0,34 -0,37 7,7%	-0,57 -0,48 -19%	-0,27 -0,45 40%	-0,54 -0,36 -48%	-0,42 -0,47 11%	-0,58	-0,50	-0,40	-0,25	-0,08
Announcement Date		11/06/2018	02/26/2019	05/01/2019	07/31/2019	10/30/2019	02/26/2020	05/07/2020	08/05/2020	11/04/2020	02/24/2021